Login
Subscribe
Opinion: Emergency Use Authorizations Are a Threat to Science
Opinion: Emergency Use Authorizations Are a Threat to Science
As COVID-19 therapies get emergency-use green lights, the Biden administration must organize a therapeutic review board to help identify what’s working and what’s not.
As COVID-19 therapies get emergency-use green lights, the Biden administration must organize a therapeutic review board to help identify what’s working and what’s not.
FDA, disease & medicine, clinical trials
A Challenge Trial for COVID-19 Would Not Be the First of Its Kind
Jef Akst | Oct 8, 2020 | 9 min read
Although scientists debate the ethics of deliberately infecting volunteers with SARS-CoV-2, plenty of consenting participants have been exposed to all sorts of pathogens in prior trials.
Remdesivir Works Against Coronaviruses in the Lab
Abby Olena, PhD | Mar 20, 2020 | 4 min read
The antiviral disables RNA replication machinery in MERS and SARS viruses. Can it beat back SARS-CoV-2?
FDA Approves Previously Rejected Muscular Dystrophy Treatment
Emily Makowski | Dec 13, 2019 | 1 min read
The drug Vyondys 53 has met a surrogate endpoint of protein production, but there’s no clear proof it has a clinical benefit.
FDA Suspends Clinical Trials Involving Fecal Transplants
Chia-Yi Hou | Jun 14, 2019 | 1 min read
The agency issued a safety warning after two patients contracted antibiotic-resistant infections and one of the patients died.
Esketamine, a Treatment for Depression, Receives FDA Approval
Carolyn Wilke | Mar 6, 2019 | 2 min read
The nasal spray to ease intractable depression appears on the US market after decades without novel antidepressant treatments.